EFTA–China FTA – Origin Cumulation Pharmaceutical Products

Quelle: https://www.efta.int/publications/economic-reports/fta-china

Origin cumulation under the EFTA–China FTA refers to the regulation that allows materials and products from certain EFTA states and China to be aggregated to determine the originating status of a final product, particularly for pharmaceutical products.

Related Terms

You might also be interested in these terms

EFTA–China FTA

The EFTA–China FTA is a free trade agreement between the European Free Trade Association (EFTA) and China aimed at promoting trade exchange by reducin...

Learn more

China–Peru FTA – Origin Cumulation of Pharmaceutical Products

The trade agreement between China and Peru allows for the origin cumulation of pharmaceutical products, meaning that materials from both countries can...

Learn more

EFTA–Chile FTA – Origin Cumulation Pharmaceutical Products

The EFTA-Chile Free Trade Agreement allows for origin cumulation for pharmaceutical products, meaning that these products can benefit from the accumul...

Learn more

CAFTA-DR – Origin Cumulation Pharmaceutical Products

CAFTA-DR – Origin cumulation refers to the mechanism under the Central America Free Trade Agreement – Dominican Republic that allows countries to appl...

Learn more

China–Costa Rica FTA – Origin Cumulation Pharmaceutical Products

The origin cumulation in the China-Costa Rica FTA allows pharmaceutical products manufactured in Costa Rica, under specified origin criteria, to be co...

Learn more

China–Chile FTA – Origin Accumulation Pharmaceutical Products

The China–Chile Free Trade Agreement (FTA) allows for origin accumulation for pharmaceutical products, meaning that products can be considered origina...

Learn more